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Abstract 
Background: Antigenic polymorphisms are considered as one of the main strategies employed by malaria parasites 
to escape from the host immune responses after infections. Merozoite surface protein-1 (MSP-1) of Plasmodium vivax, 
a promising vaccine candidate, is a highly polymorphic protein whose immune recognition is not well understood.
Methods and results: The IgG responses to conserved (MSP-119) and polymorphic (block 2 and block 10) epitopes 
of PvMSP-1 were evaluated in 141 P. vivax infected patients. Ten recombinant proteins corresponding to block 2 
(variants BR07, BP29, BP39, BP30, BEL) and block 10 (BR07, BP29, BP39, BP01, BP13) often observed in Brazilian P. vivax 
isolates were assessed by ELISA in order to determine levels of specific antibodies and their respective seroprevalence. 
The magnitude and the frequency of variant-specific responses were very low, except for BR07 variant (>40%), which 
was the predominant haplotype as revealed by block 10 PvMSP-1 gene sequencing. By contrast, 89% of patients had 
IgG against the C-terminal conserved domain (PvMSP-119), confirming the high antigenicity of this protein. Using 
multiple linear and logistic regression models, there was evidence for a negative association between levels of hae-
moglobin and several IgG antibodies against block 2 variant antigens, with the strongest association being observed 
for BP39 allelic version. This variant was also found to increase the odds of anaemia in these patients.
Conclusions: These findings may have implications for vaccine development and represent an important step 
towards a better understanding of the polymorphic PvMSP-1 domain as potential targets of vaccine development. 
These data highlight the importance of extending the study of these polymorphic epitopes of PvMSP-1 to different 
epidemiological settings.
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Background
Plasmodium vivax represents a challenge to the pub-
lic health system in the Americas with approximately 
80 million people being exposed to this malaria agent 
and about 300,000 clinical cases registered in 2013 [1]. 
Although the total number of confirmed malaria cases 
and deaths in the region has been decreased in the last 
decades, P. vivax infections in Brazil still account for 42% 
of all cases and half of the deaths due to malaria regis-
tered in the Americas [1]. Several potential challenges 
may impact the elimination efforts in Brazil where P. 
vivax accounts for more than 80% of diagnosed malarial 
infections [2] and cases of severe disease due to this spe-
cies has been reported in the Amazon endemic region 
[3–5]. Therefore, the development of an effective malaria 
vaccine is likely to contribute to a reduction of the dis-
ease burden in endemic populations. Notwithstanding 
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the public health impact caused by P. vivax, only a few 
vaccine candidates have been tested in clinical trials due 
to an unclear protective role of the potential vaccine tar-
gets (reviewed in [6–8]).
Several studies have been performed in order to iden-
tify P. vivax antigens as putative targets for vaccine 
development. The PvMSP-1, a 200  kDa protein highly 
expressed on the surface of merozoites, is one of the best-
characterized antigens. This protein contains six highly 
polymorphic domains flanked by inter and intra-spe-
cific conserved sequences [9]. Past studies on naturally 
acquired immune responses against PvMSP-1 variable 
regions showed several limitations. The most important 
is the focus of the analysis on recombinant proteins rep-
resenting only one single version of the N-terminus of 
the protein. This is illustrated with examples: only two 
cohort studies in Brazil were able to show a reduced risk 
of infection and clinical protection associated to N-ter-
minal PvMSP1-specific antibodies [10, 11]. By contrast, 
a similar association between antibody responses to 
N-terminus of PvMSP-1 and either P. vivax infection or 
asymptomatic status was not observed in another study 
conducted in Brazil and Papua New Guinea  [12]. This 
lack of consistency calls for an extended analysis where 
a broader representation of the PvMSP-1 repertoire must 
be included in further studies. With this in mind, Bastos 
and colleagues used a panel of different variants compris-
ing three polymorphic PvMSP-1 domains (blocks 2, 6 
and 10). They showed evidence for a positive correlation 
between cumulative exposure to malaria and presence 
and levels of IgG antibodies to many PvMSP-1 variant 
antigens [13].
Whilst there is strong evidence showing that anti-
PvMSP-1 antibodies are associated with cumulative 
exposure rather protection against vivax malaria, the 
relative contribution of different regions of the mol-
ecule inducing naturally acquired antibodies remains 
unknown. Therefore, a refined characterization of vari-
ant-specific immune response for different polymorphic 
domains of PvMSP-1 is required. Here the association 
of allele-specific humoral immune responses and clini-
cal parameters, as well as the association of variant-
specific antibodies to exposure, parasitaemia and age 
among non-complicated P. vivax patients were assessed. 
These antibody responses were also analysed in relation 
to the haemoglobin concentration aiming to expand cur-
rent knowledge of the PvMSP-1 variant-specific immune 
response in exposed populations.
Methods
Study population
The dataset analysed consisted of 141 non-complicated P. 
vivax mono-infected individuals randomly selected from 
a larger study described elsewhere [14]. Malaria infec-
tion was first diagnosed by microscopy examination of 
thick blood smears and then confirmed by PCR. Briefly, 
patients were recruited and treated in two different health 
centres in the Western Brazilian Amazon between Febru-
ary 2006 and January 2008: (1) 77 patients from the Hos-
pital Universitário Júlio Müller in Cuiabá (Mato Grosso 
State), where active malaria transmission does not occur; 
(2) 64 patients from the Fundação de Medicina Tropical 
Dr. Heitor Vieira Dourado in Manaus (Amazonas State), 
located in a low malaria transmission area. Patients from 
Cuiabá reported short visits to other areas in the Brazil-
ian endemic region suggesting that they had infected 
there. Patients from Cuiabá and Manaus were previously 
exposed to malaria as the median number of reported pre-
vious malaria episodes was two. All patients were exam-
ined and interviewed by a trained physician who filled in 
a questionnaire containing demographic, clinical, parasi-
tological and epidemiological questions. Haemoglobin and 
platelet levels were measured using a blood cell counter 
(ABX Pentra 90; Horiba Diagnostics, Kyoto, Japan) and 
parasite densities were determined by examination of 200 
fields at l000×  magnification under oil immersion. Writ-
ten informed consent was obtained from all study partici-
pants prior to sample collection and ethics approval was 
obtained from the Ethical Committee Research of Univer-
sidade Federal de Minas Gerais (Protocol # ETIC 060/07).
Recombinant proteins
Eleven recombinant proteins corresponding to polymor-
phic regions (blocks 2 and 10) and conserved portions 
(block 13) of the PvMSP-1 [9] were used in this study. 
Five versions of block 2 (isolates Belem, BP29, BP39, BR07 
and BP30), five versions of block 10 (isolates BP29, BP39, 
BP13, BR07 and BP01), and one version of the conserved 
block 13 (isolate Belem) were selected for the expression 
of recombinant antigens as previously described [13]. 
The 11 plasmids used here were kindly provided by Dr. 
Marcelo U. Ferreira (Universidade de São Paulo, Brazil) 
and all recombinant proteins were expressed in fusion 
to the C-terminus of Schistosoma japonicum glutathione 
S-transferase protein (GST). Briefly, PCR products were 
cloned into the pCR 2.1-TOPO vector (Invitrogen, Carls-
bad, CA, USA) and subcloned into the expression vector 
pGEX-3X (Amersham Pharmacia Biotech). Recombinant 
proteins were expressed in transformed Escherichia coli 
(BL21-DE3) and purified by affinity chromatography as 
described elsewhere [13, 15]. Fractions were analysed by 
12% SDS-PAGE and stained with Coomassie blue. Frac-
tions containing recombinant proteins with a high degree 
of purity were pooled and extensively dialyzed against 
PBS. The protein concentration was determined using 
Page 3 of 11Sepúlveda et al. Malar J  (2016) 15:559 
the BCA kit (Pierce, USA) according to the manufactur-
er’s recommendations.
Enzyme‑linked immunosorbent assay (ELISA)
ELISA for total IgG antibodies was performed as 
described elsewhere with some modifications [14]. 
Briefly, flat-bottomed 96-well microtiter plates (Max-
isorb; NUNC 4-39454; Denmark) were coated with 25 ng 
of recombinant antigens or GST (control antigen) in 
50 µl of bicarbonate-carbonate buffer (pH 9.6; 0.1 M) and 
incubated overnight at 4 °C. After four washes with 0.05% 
Tween 20 in PBS, the wells were blocked by the addition 
of 5% (wt/vol) non-fat powdered milk in PBS for 120 min 
at 37 °C. Plasma samples diluted 1:160 (50 µl/well) were 
added following incubation at 37 °C for 90 min. A peroxi-
dase-conjugated anti-human IgG (SIGMA, St Louis, MO, 
USA), diluted 1:2000, was added to each well and incu-
bated at 37  °C for 90  min. Finally, o-phenylenediamine 
(SIGMA, USA) diluted in citrate–phosphate buffer (pH 
5.0) containing hydrogen peroxide (50 μl/well) was added 
to detect monoclonal antibody binding. Fifteen minutes 
later, the reaction was stopped with 50  µl of H2SO4 4N 
and the optical density (OD) was measured at 490  nm 
using an ELISA reader (BIO-RAD Lab USA). Each sam-
ple was assayed in duplicate and antibody values were 
expressed as reactivity index (RI), which was calculated 
as the ratio between the mean OD generated by each 
duplicate and the mean OD plus three standard devia-
tions of samples from 20 Brazilian malaria-naïve blood 
donors never exposed to malaria. RIs equal or greater 
than 1.0 were scored as positive.
PvMSP‑1 gene amplification and sequencing
The block 10 polymorphic domain of the PvMSP-1 gene 
was amplified and sequenced according to protocols 
previously described [13]. The primers PVF7 (5-CCT-
TAAGAATACCGAGATTTTGCTGAAG-3 [nucleotides 
3429–3456]) and PVR3 (5-GCGATTACTTTGTCG-
TAG-3 [nucleotides 4007–3990]) were used. The 
sequences were analysed using the programs SEQUENCE 
SCANNER v1.0 (http://www.appliedbiosystems.com) 
and Bioedit v.7.0.5.3 [16]. Forty-one recovered sequences 
were aligned to other sequences previously described [9, 
13] using CLUSTAL W following the identification and 
determination of haplotypes (alleles) distribution.
Statistical analyses
The comparison of both sites, Cuiabá and Manaus, in 
terms of demographic, parasitological and laboratorial 
data was performed using either T test, Mann–Whitney 
test or Pearson’s Chi square test where appropriate. The 
McNemar test for paired samples was used to compare 
seroprevalence between pairs of antigens. The Wilcoxon 
signed-rank test for paired samples was used to compare 
the median antibody levels between pair of antigens. 
Pairwise correlation between levels of antibodies (reac-
tivity indexes) against different antigens were calculated 
using Spearman’s non-parametric coefficients. Seroprev-
alence was estimated using a threshold of 1 for the reac-
tivity indexes and the 95% Wilson confidence interval for 
proportions.
To test the association of each IgG response with 
haemoglobin concentration and platelet counts, a mul-
tiple linear regression approach was applied to the cor-
responding data considering the latter as the response 
variables. In particular, a null regression model for each 
response variable that included only the main effects of 
putative confounders (gender, age, study site, parasi-
taemia, and number of previous malaria exposure) was 
compared to an alternative model that included the same 
confounding effects plus the effect of the specific IgG 
response under testing. For the corresponding model 
comparison, likelihood ratio tests were performed in 
the corresponding data, where −log10(P value) was used 
as a measure of the strength of association (i.e., large 
values of −log10(P value) indicated a strong association 
between haemoglobin concentration and a given IgG 
response under testing). To control for multiple testing, 
the threshold for statistically significant was determined 
by the Bonferroni correction method [i.e., −log10 (overall 
significance level/number of tests performed)]. A similar 
approach was applied to analyse the association between 
anaemia (haemoglobin  <11  g/dl) or thrombocytopae-
nia (platelet  <150,000/mm3) and each IgG response but 
alternatively using a logistic regression framework due 
to binary nature of the response variables. To assess the 
quality of prediction of the fitted models, the area under 
the receiver-operating characteristic curve (AUC) was 
calculated for the models providing the strongest asso-
ciation between anaemia and IgG responses; the values 
of 0.5 and 1 correspond to a random and perfect predic-
tion of the response variable by the model, respectively. 
In particular, high values of AUC indicated a good agree-
ment between model predictions and the respective data.
All analysis were carried out in the R software version 
3.3.0 for Apple Maverick operating system (http://www.r-
project.org) using the authors’ own scripts, which are 
available from the authors upon request. The significance 
level was set at 5% for the analyses.
Results
Levels and prevalence of antibodies to polymorphic 
and conserved domains of PvMSP‑1
Patients presenting non-complicated vivax malaria 
diagnosed in two different health centres (Cuiabá and 
Manaus) in the Brazilian Amazon region were enrolled 
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in this study. The median parasitaemia significantly var-
ied between patients from Cuiabá and Manaus (1640 
vs. 3713 parasites/µl of blood, respectively; P  <  0.0001). 
However, the groups are reasonably matched for age, 
gender, number of previous malaria episodes, haemo-
globin levels, platelets count and number of white blood 
cells (Table 1).
Levels (measured as reactivity indexes) and seropreva-
lence of plasma IgG antibodies to 10 antigens represent-
ing allelic forms of PvMSP-1 (BR07, BP29, BP39, BP30 
and BEL of block 2 and BR07, BP29, BP39, BP01 and 
BP13 of block 10) and to one conserved antigen repre-
senting block 13 (PvMSP-119) are showed in Fig. 1a and b, 
respectively. As expected, the levels of IgG antibodies to 
PvMSP-119 were significantly higher than those observed 
to other polymorphic antigens representing block 2 or 
block 10 of PvMSP-1 (all P values  <0.001) (Fig.  1a). In 
close agreement with this observation is the high sero-
prevalence of patients with antibodies against PvMSP-
119 (87.9%) that contrasts with the low seroprevalence of 
the remaining antigens representing the variable region 
of the PvMSP-1 molecule. Among those, version BR07 
of both block 2 and block 10 were the most recognized 
variable antigens (42.6 and 36.9%, respectively) (Fig. 1b). 
The other recombinant variable antigens were poorly 
recognized by P. vivax patients revealing seroprevalence 
no greater than 30%. Similar patterns were observed for 
plasma IgG levels confirming the poor antigenicity of 
variable antigens of PvMSP-1 as compared to conserved 
block 13, PvMSP-119 (Fig. 1a).
Antibody responses to polymorphic blocks of PvMSP‑1 
and their association with infecting parasites
Ten out of 141 patients had no detectable IgG response 
to any antigen of the PvMSP-1 despite their current 
clinical infection (Fig. 2a). For PvMSP-1 responders, the 
proportion of patients who seroreacted to the conserved 
C-terminal PvMSP-119 antigen was significantly higher 
than the proportion of patients that seroreacted to any 
variant antigen of block 2 or block 10. To assess the 
contribution of PvMSP-119 determining such high anti-
body recognition rate, the range of positive responses 
(against one to 11 antigens tested) among 141 patients 
with positive IgG responses were analysed. As shown 
in Fig. 2a, the frequencies of seropositive patients who 
presented antibodies exclusively to any variant antigens 
were very low. Further, the overall combined frequency 
of antibody responses to all block 2 and block 10 vari-
ant antigens was significantly lower than that to C-ter-
minal PvMSP-119, a result that suggests a high natural 
diversity of past and current P. vivax infections. In line 
with this observation is the increased total number of 
seropositive antigens per individual as a function of the 
self-reported number of previous malaria cases. This 
high diversity of IgG response profiles is also captured 
by the combined seroprevalence profiles to block 2 and 
block 10 recombinant antigens shown in Fig. 2b and c, 
respectively.
Sequences of the PvMSP-1 gene were obtained from a 
total number of 41 infected patients. These 41 sequences 
comprised eight different haplotypes from the block 10 
PvMSP-1 gene (see Additional file 1: Figure S1). Interest-
ingly, version BR07, an isolate firstly collected in Porto 
Velho, the capital of Rondonia state (Western Brazilian 
Amazonia) in 1995, was the most common sequence 
among those 41 typed isolates (32%). The amino acid 
sequences of five haplotypes were identical to those of 
the antigens used for antibody measurements and were 
detected in 30 local variant sequences suggesting an ade-
quate panel of antigens used for serology. Four sequences 
Table 1 Demographic, parasitological and laboratorial data of the 141 patients infected by Plasmodium vivax
Significant P values are indicated in italics
Characteristic Median values (interquartile range) P value
Cuiabá (n = 77) Manaus (n = 64)
Age (years) 39 (26–48) 38 (27–49) 0.91
Gender (male %) 76.6 67.1 0.26
Number of previous episodes [n (%)] 0.07
 0 16 (20.8) 19 (29.7)
 1–5 38 (49.4) 36 (56.2)
 >5 23 (29.9) 9 (14.1)
Parasitaemia (parasites/µl) 1640.0 (686.5–2855.0) 3713.0 (1838.0–6733.0) <0.0001
Haemoglobin (g/dl) 13.20 (11.50–14.30) 13.00 (12.15–14.50) 0.63
Platelets (cells/mm3) 107,000 (75,000–154,500) 100,000 (73,000–157,750) 0.54
White blood cells (cells/mm3) 5600 (4560–7250) 5000 (4300–6675) 0.06
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identified as type II, III, VI and VIII which present 100% 
of similarity to sequences of recombinant antigens BP13, 
BP29, BP01 and BP39 were recovered at frequencies of 
7.3, 14.6, 9.8 and 9.8%, respectively (see Additional file 2: 
Table S1). Note that 11 isolates (28.6%) share less than 
75% of amino acid identity with sequences of the antigens 
used but had homology with other antigen sequences: 
haplotypes V and VII showed similarities of up to 90% 
Fig. 1 Antibody data for P. vivax patients. a Box plots of reactivity index of IgG antibodies to variable (block 2 and block 10) and conserved (block 
13) recombinant antigens of PvMSP-1. Antibody reactivity of PvMSP-119 antigen is statistically higher than that of each variant PvMSP-1 antigen 
(Wilcoxon signed-rank test, all P values <0.001). b Prevalence of seropositivity to each IgG responses and respective 95% confidence intervals, where 
seropositivity was determined as the reactivity index greater than 1. Seroprevalence of PvMSP-119 antigen is statistically higher than that for each 
variant PvMSP-1 antigen (McNemar test, all P values <0.001)
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with Asian isolates and haplotype IV showed a similar-
ity rate of 100% with another Brazilian isolated, BP30 not 
tested in our study.
Weak associations between levels of IgG antibodies 
and variants belonging to the same block of PvMSP‑1
A correlation analysis was performed between a pair of 
IgG antibodies against to 10 variant recombinant pro-
teins among either the overall population (141 patients) 
or IgG responders for each pair of antigens simultane-
ously recognized. Most of the correlations provided 
evidence for weak associations between IgG levels to 
variants antigens belonging to the same block of PvMSP-
1. Cross-reactivity between versions BR07 and both BR29 
and BP30 of the block 2 and BP01 and both BP29 and 
BP39 of the block 10 were detected among IgG respond-
ers (Fig. 3). In contrast, those antigenic pairs of block 2 
(BR29-BR07) and block 10 (BP01-BP29 and BP01-BP39) 
showed a moderate proportion of amino acid identity 
(69.6–77.1%) as previously reported [13]. Interestingly, 
inter-block positive correlations could be verified either 
among the overall population or IgG responders. For 
example, levels of IgG to BELEM version of the block 2 
were moderately correlated to IgG levels to BP01 version 
of block 10. The same pattern was observed for the cor-
relation between BP29 versions from either block 2 and 
block 10. Negative correlations were also obtained for 
inter antigenic blocks revealing five putative block 2–
block 10 antigens pairs among responders (Fig. 3).
Correlation between antibodies to PvMSP‑1 and anaemia
Multiple linear and logistic regression models were then 
used to determine whether platelets counts, haemoglo-
bin levels or anaemia could be associated with each IgG 
antibody response to PvMSP-1 adjusting for putative 
confounding effects (i.e., locality, age, gender, parasitae-
mia and a total number of previous malaria episodes). 
Haemoglobin levels were associated with IgG antibody 
Fig. 2 Frequencies of allele-specific IgG responses to PvMSP-1. a Frequency distribution of the total number of seropositive responses to conserved 
(PvMSP-119) and variant antigens PvMSP-1 antigens. b Frequency distribution of different joint seropositivity profiles for block 2 variant antigens: 
BELÉM (BEL), BP30, BP39, BP29, and BR07 antigens. c Frequency distribution of different joint seropositivity profiles for block 10 variant antigens: 
BP13, BP01, BP39, BP29, and BR07 antigens
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responses to not only the C-terminal of PvMSP-1 domain 
PvMSP-119 but also with four among five variant anti-
gens representing block 2 region (BR07, BP29, BP39, 
and BEL). The strongest association observed with hae-
moglobin levels refers to the IgG response to block 2 
variant antigens, BP39. The respective association would 
appear to be negative as suggested by the negative esti-
mate for antibody-level coefficient for the respective data 
(Table 2). None of the antibody responses to five antigens 
of the variable block 10 were associated with the underly-
ing haemoglobin levels (Fig. 4). With respect to anaemia, 
there is only a strong association with IgG response to 
block 2 variant antigens, BP39. In close agreement with 
the haemoglobin data, this IgG response would appear to 
increase the odds of anaemia (Table 2). Finally, data sug-
gests no strong association between platelet counts or 
thrombocytopaenia and any IgG response.
Discussion
MSP-1 has been considered one of the most promis-
ing molecules to be included in an anti-malarial subunit 
vaccine. However, its high allelic diversity observed in 
distinct Plasmodium isolates [16] might be one of the 
factors contributing to unsatisfactory results in the sub-
sequent vaccine development. In fact, antigenic polymor-
phisms displayed by malaria parasites are considered as 
one of the strategies employed by them to escape from 
the host immune responses after recurrent infections 
[17]. Here, naturally acquired antibodies were studied in 
P. vivax infected patients from low and unstable malaria 
transmission settings. The results showed poor antigenic-
ity of allelic variant antigens representing both block 2 
and block 10 of PvMSP-1 in opposition to the high anti-
genicity of the conserved C-terminal, PvMSP-119. The 
high magnitude of IgG response to the conserved C-ter-
minal domain of the PvMSP-1 protein that is the only 
fragment that remains attached to the merozoite surface 
during erythrocyte invasion [18, 19] is an expected result 
and confirms previous data from several serological stud-
ies conducted in different epidemiological settings in the 
Brazilian endemic area [20–26].
A weak recognition of the antigens representing varia-
ble domains of PvMSP-1 was described in this study. This 
result is in contrast with a higher degree of recognition 
of variant proteins of blocks 2 and 10 (91.3 and 100% for 
at least one variant antigen of each block, respectively) 
among 27 subjects who were infected with P. vivax in a 
rural area in northwestern Brazil [13]. This contrasting 
evidence can be explained by several factors such as dif-
ferences in the age of the patients, in the transmission 
level and geographical location and, in the stage of infec-
tion or in the degree of past exposure of the sampled indi-
viduals. In this study, the total number of ‘seropositive’ 
antigens per individuals increases with the self-reported 
number of previous malaria episodes. Similarly, an asso-
ciation between allelic-specific IgG responses to block 
Fig. 3 Pairwise correlation based on Spearman’s non-parametric coefficient between levels of IgG antibodies (reactivity index) to variant recombi-
nant antigens of block 2 and block 10 of PvMSP-1 among overall population (n = 141 patients) and among responders to specific proteins (green 
correlation <−0.5, yellow—(−0.5) ≤ correlation ≤0.5, red—correlation >0.5)
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10 of PvMSP-1 antigens and the time of residence in the 
endemic Amazonian region was previously reported [13].
The seroprevalences concerning the BR07 version of 
both block 2 and block 10 were found to be higher as 
compared to other variant recognition. Indeed, this ver-
sion was also found in relatively high frequency in infect-
ing parasites based on sequencing of block 10 PvMSP-1 
gene (32%). More importantly, there are 10 out of 13 
(77%) patients carrying this specific haplotype that were 
seropositive against this recombinant protein. By con-
trast, Belem isolate has been previously reported as the 
predominant variant haplotype in a sample of P. vivax 
parasites living in the Manaus municipality (one of the 
same areas studied here) based on block 2 of PvMSP-1 
sequencing [27]. In the present study, no sequencing of 
the block 2 of PvMSP-1 gene was performed. The respec-
tive serological data suggests a low seroprevalence for 
such antigen but it is unclear how this seroprevalence 
Table 2 Association analysis between antibodies against BP39 version of block 2 of PvMSP-1 and haemoglobin concen-
tration (linear regression) and anaemia (logistic regression)
Coefficient Haemoglobin concentration Anaemia
Estimate SE P value Estimate SE P value
Intercept 15.70 62.69 <0.001 −5.835 1.521 <0.001
Age (in years) −0.015 0.010 0.164 0.035 0.023 0.131
Gender −1.557 0.313 <0.001 2.198 0.676 0.001
Malaria episodes
 1–5 0.231 0.354 0.516 −1.222 0.711 0.086
 >5 0.447 0.425 0.296 −1.825 0.966 0.059
Municipality (Manaus) 0.720 0.311 0.022 −2.501 0.894 0.005
Parasitemia (per 1000 parasites) −0.111 0.039 0.005 0.205 0.918 0.025
Antibody level −0.481 0.105 <10−5 0.629 0.220 0.004
Fig. 4 Associations between each IgG level and haemoglobin concentration (linear regression analysis) and anaemia (logistic regression model) 
where −log10(P value) is a measure of the strength of association and the dashed line refers to the threshold ensuring a 5% global statistical signifi-
cance using the Bonferroni multiple testing correction
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relates to the frequency of parasites bearing this specific 
haplotype.
The results showed a weak antigenicity of block 2 
and block 10 variable domains. Such weak response is 
unlikely to be explained by the restricted panel of recom-
binant proteins used here. In fact, the set of antigens 
used to measure IgG responses among P. vivax infected 
patients would appear to be appropriate since approxi-
mated 60% of the amino acid sequences recovered were 
identical to those of the antigens used and being detected 
in 30 out of 41 local variant sequences. The most likely 
explanation is the small contribution of each haplotype 
to the circulating population. However, this explana-
tion remains to be confirmed with a higher number of 
sequenced P. vivax parasites and a larger set of samples 
from exposed individuals.
Association between the specificity of circulating anti-
bodies and variants of P. falciparum infecting parasites 
has been extensively investigated in different endemic 
regions. No correlation between the allele-specific anti-
body response and variants of MSP-1 or MSP-2 circu-
lating parasites were described in populations living in 
the Brazilian Amazon endemic region [28, 29]. How-
ever, it is much less clear about the association between 
allelic specific antibodies and PvMSP-1 sequences found 
in circulating parasites. In fact, only a single work has 
demonstrated frequent mismatches between PvMSP-1 
sequences in infecting parasites and the antigenic vari-
ants recognized by IgG antibodies in the Brazilian Ama-
zon endemic region [13].
Here, weak correlations between IgG responses were 
observed in pairs of variable antigens with high amino 
acid identity (>90%) contrasting data from that previous 
work conducted among 27 patients with acute P. vivax 
infection living in Acre state [13]. Therefore, the limited 
data available from PvMSP-1allele-specific antibodies 
undermined the possibility of discussing the deeper con-
tribution of antigenic polymorphism on modulation of 
the naturally acquired immune response. In fact, even for 
vaccine based on PfMSP-1 which elicited antibodies that 
inhibited the growth of three diverse P. falciparum iso-
lates in vitro [30] none protection against clinical malaria 
caused by diverse parasites in the field could be observed 
[31].
A dual role for specific antibodies against P. falcipa-
rum or P. vivax infection has been suggested for both 
immunity and pathogenesis of malaria (reviewed in [32]). 
Therefore, it was a reasonable hypothesis to investigate 
whether naturally acquired antibodies against conserved 
and variant PvMSP-1 proteins were associated with anae-
mia, a clinical parameter considered to be one of the 
major complications in P. vivax infections. The results 
suggested that none of the antibody responses to variable 
block 10 was associated with the haemoglobin levels of 
the sampled patients. However, haemoglobin levels were 
negatively correlated with IgG antibody responses to four 
variant antigens of block 2 domain (BR07, BP29, BP39, 
and BEL). These results are in agreement with a previous 
study that showed an association with an increased risk 
of infection and antibodies to block 2 of MSP-1 of P. fal-
ciparum [33].
The association between anaemia and serology specific 
has been suggested for antibodies against to P. falcipa-
rum rhoptry-associated proteins [34, 35]. In relation to 
P. vivax, parasitic antigens were detected on the surface 
of infected human RBCs [36] and an association between 
specific antibodies to PvMSP3 and anaemia has also been 
found [14]. It is possible to speculate that, during the 
proteolytic processing, PvMSP-1 polypeptides repre-
senting block 2 and block 10 domains could bind to the 
surface of infected or non-infected erythrocytes, form 
immune-complexes and stimulate phagocytosis or com-
plement-mediated lysis. However, the precise mechanism 
underlying the association between anaemia and the role 
of specific antibodies determining such haematological 
disorder during malarial infection is still elusive and out 
of the scope of the present study.
Levels of IgG antibodies against PvMSP-119 were 
found to be negatively associated with the haemoglobin 
levels. No statistically significant association was found 
between anaemia and the same antibodies. These two 
results might be explained by the IgG subclass distri-
bution among serum samples from P. vivax patients. In 
a previous study on the same sample, anti-PvMSP-119 
non-cytophilic IgG2 and IgG4, as well as the cytophilic 
IgG3 antibodies, were detectable at similar proportions 
(approximately 50%) and levels [14]. Such non-cytophilic 
antibodies may block protective mechanisms such as 
parasite killing in cooperation with blood monocytes 
(ADCI) for P. falciparum [37]. This rationale may be then 
extended to explain the associations between antibodies 
to block 2 variant antigens and anaemia. Notwithstand-
ing the fact that this study did not intend to character-
ise the subclass immune response to variable domains of 
PvMSP-1, it is yet possible that among patients infected 
by P. vivax who reported a short-term exposure to 
malaria transmission could present high proportions of 
non-cytophilic antibodies blocking any protective mech-
anism involved. In fact, block 2 domain of MSP-1 of P. 
falciparum has been considered an important target of 
ADCI mechanism [38]. However, the lack of an appropri-
ate P. vivax culture method and the difficulties involved 
in performing in vivo assays using this species limit the 
tools available to test this hypothesis.
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Conclusions
Despite the limitations of the present study that under-
mined a deeper analysis towards the true causal rela-
tionships between allele-specific antibodies to block 2 
of PvMSP-1 and anaemia, some of the conclusions are 
a step forward towards a better understanding of poly-
morphic domains as potential targets of vaccine develop-
ment. Further studies are necessary to better understand 
the balance between the putative benefit of triggering an 
immune response and the possible deleterious effects of 
increasing the risk of anaemia.
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